Fantacuzzi M
ORCID: 0000-0003-2401-7547
· 1 paper in corpus
2025
Background: Third-generation aromatase inhibitors (CYP19A1) are the mainstay of treatment for estrogen-receptor-positive breast cancer. This is because estrogen is required for cancer growth in approximately 70% of patients with this condit…